UroGen Pharma Ltd. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $887.00K, a 198.65% increase year-over-year.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $179.00K, a 496.67% increase year-over-year.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $1.34M, a 1791.55% increase year-over-year.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $302.00K, a 162.61% increase year-over-year.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for fiscal 2025 was $1.97M, a 514.33% increase from fiscal 2024.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for fiscal 2024 was $321.00K, a 63.23% decline from fiscal 2023.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for fiscal 2023 was $873.00K, a 42.22% decline from fiscal 2022.
- UroGen Pharma Ltd. stock issued during period, value, stock options exercised for fiscal 2022 was $1.51M, a 2377.05% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $887.00K 10-Q · filed 2026-08-05 | $2.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $179.00K 10-Q · filed 2026-05-06 | $2.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.97M 10-K · filed 2026-03-02 |
| 2025-09-30 | $302.00K 10-Q · filed 2025-11-06 | $700.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $297.00K 10-Q · filed 2026-08-05 | $513.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $30.00K 10-Q · filed 2026-05-06 | $351.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $321.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $115.00K 10-Q · filed 2025-11-06 | $290.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $135.00K 10-Q · filed 2025-08-07 | $193.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $201.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $873.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $18.00K 10-Q · filed 2024-11-06 | $1.21M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $143.00K 10-Q · filed 2024-08-13 | $2.31M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $672.00K 10-Q · filed 2024-05-13 | $2.18M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.51M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.12M 10-Q · filed 2023-11-14 | $1.13M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $16.00K 10-Q · filed 2023-08-10 | $19.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $57.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $61.00K 10-K · filed 2022-03-21 |
| 2021-09-30 | $3.00K 10-Q · filed 2022-11-10 | $110.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $54.00K 10-Q · filed 2022-08-11 | $295.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.00K 10-Q · filed 2022-05-10 | $451.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $740.00K 10-K · filed 2022-03-21 |
| 2020-09-30 | $188.00K 10-Q · filed 2021-11-15 | $1.01M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $210.00K 10-Q · filed 2021-08-04 | $1.95M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $293.00K 10-Q · filed 2021-05-13 | $1.91M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $3.66M 10-K · filed 2021-03-18 |
| 2019-09-30 | $1.12M 10-Q · filed 2020-11-09 | $4.69M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $172.00K 10-Q · filed 2020-08-10 | $4.62M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $2.05M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.40M 10-K · filed 2020-03-02 |
| 2018-09-30 | $1.05M 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $71.00K derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $404.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $329.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | |
| 2017-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | |
| 2017-03-31 | $4.00K 6-K · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |